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South African amaXhosa patients with atopic
dermatitis have decreased levels of filaggrin
breakdown products but no loss-of-function
mutations in filaggrin
To the Editor:
Loss-of-function (LOF) mutations in the filaggrin gene (FLG)
are the strongest known genetic risk factors for atopic dermatitis
(AD). The genetic architecture of FLG mutations is well estab-
lished in European, Japanese, and selected Chinese populations,
but their contribution to AD in African populations is not well un-
derstood. The only data on FLGmutations in Africans come from
a recent study conducted in Ethiopia1 that studied 103 patients
with AD, 7 patients with ichthyosis vulgaris (IV), and 103 healthy
controls. This study identified only a single novel mutation (a 2-
bp deletion, 632del2), by direct sequencing of FLG in a patient
with AD.
To investigate the role of filaggrin in the etiology of AD in
South Africa, we studied 69 children with AD from the amaXhosa
community along with 81 age-, ethnic- and sex-matched controls,
with no history of AD. The patients (n5 69) and controls (n5 81)
were recruited from tertiary referral AD clinics in Cape Town.
Clinical and demographic characteristics of control subjects and
patients with AD are outlined in Table I. The study was conducted
in accordance with the Helsinki Declaration and was approved by
the Human Research Ethics Committee of the Faculty of Health
Sciences of the University of Cape Town. Written consent/ascent
in the amaXhosa language was obtained from the patients or their
parents.
The entire coding sequence of the FLG gene was directly
sequenced (as described previously2) in 31 patients with AD
with prominent features of IV, that is, those who should most
likely have FLGmutations. Sequencing of PCR products was per-
formed by a core facility (DNA Sequencing and Services, Univer-
sity of Dundee, Dundee, United Kingdom) according to our
standard operating procedures. The entire collection was addi-
tionally typed for the previously known FLG mutations R501X,
2282del4, R2447X, and S3247X by using custom-made Taqman
allelic discrimination assays.2 Although the primers used for the
amplification of the FLG gene were originally optimized for thesequencing of European populations,2 in the 31 amaXhosa pa-
tients with AD who were sequenced, we identified 124 mutations
(synonymous and nonsynonymous) throughout exon 3 of theFLG
gene by using these methods. Identification of these silent and
nonpathogenic missense mutations in the FLG gene indicates
minimal allele dropout using these primer sets. None of these
identified mutations was predicted to lead to loss of filaggrin at
the protein level. Screening of the entire collection of patients
for the FLG mutations R501X, 2282del4, R2447X, and S3247X
showed that all samples were wild type for these mutations.
In addition to gene sequencing, in all patients with AD and
controls, we determined the concentrations of filaggrin break-
down products in the stratum corneum (SC). Filaggrin is degraded
in the later stages of epidermal differentiation into free amino
acids (FAA) and their derivatives; a major proportion of the total
SC FAA (70% to 100%) is derived from filaggrin.3 Themost com-
mon amino acid residues in filaggrin repeats are basic amino acids
such as histidine (413 of 4061 residues; 10.17%) and arginine
(440 of 4061 residues; 10.83%) and the polar residue glutamine
(367 of 4061; 9.04%) (see Fig E1 in this article’s Online Repos-
itory at www.jacionline.org). Histidine is enzymatically deami-
nated to trans-urocanic acid (trans-UCA).3 Trans-UCA, which
is converted to cis-UCA on ultraviolet irradiation, functions as
a major chromophore and exerts immunomodulatory effects in
the skin.3,4 UCA maintains an acidic pH in the skin, which is
crucial for the optimal function of several enzymes in the SC
and antimicrobial defence.3,4 Another abundant amino acid gluta-
mine is further converted into pyrrolidone-5-carboxylic acid
(PCA). PCA is highly hygroscopic and is one of the major com-
ponents of the natural moisturizing factor, thus providing a hu-
mectant effect by retaining water in the SC.3,4 Filaggrin
degradation products thus have multiple functions.
FLG mutations lead to reduced levels of filaggrin degradation
products in the SC in a dose-dependent fashion.5 It has been
shown that moderate-to-severe AD also has an effect on SC filag-
grin expression6 as well as on the levels of filaggrin degradation
products5 possibly due to the systemic TH2 immune response.
6
In the present study, the levels of both PCA and UCA and their
sum were significantly decreased in the SC of patients with AD
than in control subjects (Fig 1; see Table E1 in this article’s Online
Repository at www.jacionline.org). The magnitude of reduction
between cases and controls in this study was approximately
20%. Similar results were obtained when comparing total FAA
content as well as total FAA including their derivatives, PCA,
UCA, citrulline, and ornithine (Fig 1; Table E1). While FLGmu-
tations are the major determinants of the level of filaggrin break-
down products in the SC, it has been previously shown that their
levels are significantly reduced in European populations both in
nonlesional skin of patients with AD with FLG mutations and
in patients without FLG mutations.5 In this study, we have repli-
cated these filaggrin breakdown product findings in patients with
AD without FLG mutations in an African population. This is
consistent with the in vitro findings of Howell et al6 and Pellerin
et al7 and highlights the fact that there is an interplay between
the skin barrier and a systemic immunologic process, with sys-
temic TH2 inflammation causing a decrease in SC filaggrin
expression.
The SC profiles of filaggrin breakdown products are highly
informative in this African population because they provide a
second look, in addition to direct sequencing, for FLGmutations.
In our study, we demonstrate that the diminution of filaggrin
FIG 1. Levels of filaggrin degradation products in the SC of healthy controls (Ctrl, n 5 81) and patients
with AD (n 5 69) (median with interquartiles). FAA 1 derivatives, FAA including UCA, PCA, citrulline, and
ornithine. ***P < .001 as determined by the 2-tailed Wilcoxon-Mann-Whitney test.














CTRL 81 5 (1-31) 43 (53) — — — — —
Patients with AD 69 9 (4-29) 36 (52) 10 (4-15) 57, 2114 (12-10500) 68 of 69 21 of 69 60 of 69
CTRL, Healthy controls; NESS, Nottingham Eczema Severity Score.
*AD was diagnosed by an experienced dermatologist by using the UK diagnostic criteria.
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ropean patients with AD who are wild type for FLG mutations.
The magnitude of this reduction is much less than that seen in pa-
tients with AD with FLGmutations, even in African patients with
clinical findings consistent with IVwho could be expected to have
FLG mutations. In Europeans with a single FLG LOF mutation,
expression of these products is reduced by approximately 50%.5
We here provide strong and complementary evidence for an
absence of FLG mutations in this African population through 2
analytical methodologies. Given that FLG mutations are well es-
tablished as the strongest andmost important risk factor for AD in
European, Japanese, and Chinese populations, this work clearly
implies significant genetic heterogeneity between AD in the Afri-
can population and AD in these populations. The genetics of AD
is not well studied in African populations; in addition to the Ethi-
opian study referenced earlier, 2 studies in AfricanAmerican pop-
ulations have found low frequencies of European-derived FLG
mutations,8,9 presumably due to European population admix-
ture.10 While it is tempting to speculate, on the basis of this
work, that there could be a major (non-FLG) African-specific
gene for IV and/or AD, African populations will require specific
studies and dedicated collections to disclose African
population-specific major genetic risks for AD.In conclusion, FLG LOF mutations are not a significant
contributor to AD in the amaXhosa population. When combined
with previous findings in the Ethiopian population, the contribu-
tion of thesemutations toAD inAfricans seems to be at great vari-
ance with their major role in European and Asian populations.
Further work is required in African populations to better under-
stand the genetic basis of AD in these populations.
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FIG E1. Amino acid composition of filaggrin. Ala, Alanine; Arg, arginine; Asn, asparagine; Asp, aspartate;
Cys, cysteine; Gln, glutamine; Glu, glutamate; Gly, glycine; His, histidine; Ile, isoleucine; Leu, leucine;
Lys, lysine;Met, methionine; Phe, phenylalanine; Pro, proline; Ser, serine; Thr, threonine; Trp, tryptophan;
Tyr, tyrosine; Val, valine.
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TABLE E1. The levels of filaggrin degradation products and differences between healthy controls and patients with AD with
corresponding 95% CIs
Filaggrin degradation product* (mmol/g protein)
Median (range)
Difference (95% CI) P valueCTRL AD
PCA 0.60 (0.11-1.10) 0.49 (0.10-1.18) 20.11 (20.181 to 20.068) <.0001
UCA 0.19 (0.03-0.33) 0.15 (0.03-0.55) 20.043 (20.063 to 20.017) .0006
FAA 2.32 (0.51-3.70) 1.82 (0.62-3.67) 20.51 (20.60 to 20.18) .0005
FAA 1 derivatives 3.44 (0.72-5.40) 2.82 (0.98-5.34) 20.62 (20.91 to 20.29) .0002
*PCA and UCA have been determined by HPLC from the SC samples collected by adhesive tape strips as described elsewhere (Dapic I, Jakasa I, Yau N, Kezic S, Kammeyer A.
Evaluation of an HPLC method for the determination of natural moisturizing factors in the human stratum corneum. Anal Lett 2013;46:2134-44.) FAA and their derivatives from
the SC tapes were analyzed by using ultra performance liquid chromatography-tandem mass spectrometry. The concentrations are expressed as mmol of each component/g of
protein to compensate for variable harvest of the SC.
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